Bioabsorbable Therapeutics

Bioabsorbable Therapeutics, Inc. was a medical device company focused on developing fully absorbable stents for treating peripheral and coronary vascular disease. Founded in 2004 and headquartered in Menlo Park, California, the company operated in the therapeutic devices industry. The firm's core technology involved proprietary anti-inflammatory polymers to create both bioabsorbable coatings and stent structures. This approach aimed to provide temporary vessel support during the healing process, after which the implant would fully resorb, eliminating the long-term risks associated with permanent metallic stents.

The company's product pipeline included the Whisper coronary stent system, which was a balloon-expandable, fully absorbable stent, and the Unison Peripheral Stent System, a self-expanding version for peripheral arteries. A key feature of their technology was a polymer backbone constructed from repeating salicylate molecules which, during absorption, would hydrolyze and release salicylic acid, an anti-inflammatory agent, directly at the treatment site. Bioabsorbable Therapeutics raised a total of $9.8 million in funding over several rounds, with a significant Series B round of $9 million in 2007 led by investors such as Finistere Ventures and ITX International Holdings. In September 2010, the company was acquired by Xenogenics for an undisclosed amount.

Keywords: bioabsorbable stents, vascular disease, therapeutic devices, coronary stents, peripheral stents, absorbable polymers, interventional cardiology, medical devices, drug-eluting stents, polymer technology